GREY:MDCGF - Post by User
Post by
TechnicalBuyon Sep 06, 2010 2:27pm
529 Views
Post# 17417727
Update
UpdateI will likely be sending an update tomorrow. Despite the financing fiasco, Medicago remains a compelling buy for a number of reasons, main one being the cost advantage. With the current plant facility details available we can do a comparison to a similar facility by Novartis. In Nov of 2009 Novartis started building a 150M dose/6months, $1B cell-culture manufacturing facility. Expected completion was in 2013. Compare that to Medicago's 120M dose/year, $42M facility that will be complete in a year.
The pressure is on for MOU partners to complete their deals for a number of reasons. NVAX had just completed a VLP influenza plant in India. With Medicago having a gov't partner in the biggest market all other deals are simply not as important and will likely need to provide better terms.
Once the share paddling ends and the news start to roll I think there will be a lot of interest in the stock.
Stay tuned...
TB
www.technicalbuy.com